Visiting Dana-Farber? See our prescreening and mask requirements.
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
The Center for Cutaneous Oncology has been associated with the National Cancer Institute-supported Specialized Program of Research Excellence (SPORE) since 2001. The Harvard Skin Cancer SPORE is the first of its kind in the U.S. designed to speed laboratory insights directly to patient care. Many of our physicians who treat patients with skin cancer are involved in the research associated with the SPORE grant.
The Center for Cutaneous Oncology has a variety of clinical trials available. You can enroll in our blood, tissue, and database collection studies for cutaneous T cell lymphoma (CTCL) or Merkel cell carcinoma (MCC). The goal of this research is to understand the genetic and biologic factors that may contribute to the development of CTCL and MCC, and to better understand why tumors develop.
The Center for Cutaneous Oncology has a variety of targeted therapeutic clinical trials for the treatment of CTCL, MCC and basal cell carcinoma (BCC).
For more information regarding enrollment and eligibility, please call 617-632-6571.
New Patient Appointments 877-442-3324
Clinical Trials Questions?
877-DF-TRIAL (877-338-7425)